Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan:19 Suppl 1:3-5.
doi: 10.1111/jth.15188.

Safety first: Tracking adverse events associated with new therapies for people with hemophilia

Michael Recht  1   2
Affiliations
Free article

Safety first: Tracking adverse events associated with new therapies for people with hemophilia

Michael Recht. J Thromb Haemost. 2021 Jan.
Free article
No abstract available

Keywords: clinical research; emicizumab; hemophilia; mortality; registry.

PubMed Disclaimer

References

REFERENCES

    1. Schwartz RS, Abildgaard CF, Aledort LM, et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in treatment of hemophilia A. Recombinant factor VIII study group. N Engl J Med. 1990;323(26):1800-1805.
    1. Inwood M, Lusher J. Clinical trials of the recombinant factor VIII product, Kogenate. Transfusion Med Rev. 1992;6(4):261-262.
    1. Hemophilia: From plasma to recombinant factors. http://www.hematology.org/about/history/50-years/hemophilia. Accessed October 11, 2020.
    1. Gringeri A. Factor VIII safety: plasma-derived versus recombinant products. Blood Transfus. 2011;9(4):366-370.
    1. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;31(377):809-818.

MeSH terms